# A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

> **NCT04811196** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 56 (actual)

## Conditions studied

- Soft Tissue Sarcoma
- Malignant Peripheral Nerve Sheath Tumor (MPNST)
- Leiomyosarcoma
- Endometrial Stromal Sarcoma

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT04811196
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-05-15
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04811196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04811196, "A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04811196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*